Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1993-01-27
1996-03-12
Sidberry, Hazel F.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
4242041, 424818, 435 693, 4353201, 530350, 530826, A61K 3923, C12N 1535, C12N 1563, C07K 14015
Patent
active
054984130
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates in general to viral proteins and to assays and vaccines using the same and, in particular, to a protein related to the major antigen (VP2) of the Porcine Parvovirus (PPV) capsid. Such protein was produced in an expression vector of baculoviruses multiplied in a cell culture of a permissive host.
BACKGROUND OF THE INVENTION
The Porcine Parvovirus (PPV) causes reproductive failure in swine, resulting in death and foetal mummification, still births and other reproductive failures in pregnant sows. (Joo & Johnson. 1976. Veterinary Bulletin 46, 653-660; Mengeling. 1978. J. Am. Vet. Med. Assoc. 172, 1291-1294). PPV is an autonomous parvovirus containing a single strand DNA molecule of approximately 5000 nucleotides (Mollitor et al. 1984. Virology 137, 241-254). The complete sequence of this genome has been recently described by our group (Ranz et al. 1989. J. Gen. Virol. 70, 2541-2553). Four virus-specific proteins have been described: three capsid proteins (VP1, VP2 and VP3 of Mr values 83000, 64000 and 60000 daltons, respectively) and one non structural protein NS1.
The PPV is related to the Kilham rat virus (KRV) group of autonomous parvoviruses formed by KRV, minute virus of mice (MVM), LuIII, H-1, Feline Panleukopenia virus (FPV), canine parvovirus (CPV) and the mink enteritis virus (MEV). These viruses share several common features with other autonomous parvoviruses: DNA replication and the right ORF encodes the major capsid proteins as a nested set.
To date, there are several vaccines protecting from porcine parvovirus disease, which are based on conventional inactivation methods of the virus. However, every previous attempt of new vaccines production using recombinant proteins produced in procariotic microorganisms (v.g. E. coli) have failed. In this invention, a new process is described for obtaining a new kind of vaccines based on the immunogenic properties of the major protein VP2, expressed in a baculovirus system multiplied in a cell culture of a permissive host.
For the last years, our laboratory has been studying with great detail the molecular biology of PPV. The findings obtained thus are summarized in two pioneer publications: Parvovirus: DNA sequence and genome organization. J. Gen. virol. 70, 2541-25463. infectious genomic clone of PPV. Effect of the 5' end on DNA replication. Virology 177, 764-767.
These publications are related with the knowledge of the viral DNA sequences encoding the proteins forming the vital capsid. These sequences allowed the identification of the gene that encodes the VP2 of PPV and its manipulation and insertion into the specific vectors to be expressed in the baculovirus system. This system allows a large-scale protein production based upon the replication of recombinant baculovirus derived from the Autographa californica nuclear polyhedrosis virus (AcMNPV) in insect cell cultures. The state of the art for these vectors is summed up in two scientific papers as follows: baculovirus expression vectors. Bio/Technology 6, 47-55. proteins of Measles virus using a novel baculovirus vector containing the .beta.-galactosidase gen. J. Virol. 64, 37-50.
The advantages of VP2 protein synthesis in a baculovirus vector are remarkable over the virus production in cell culture and subsequent purification, in the economic cost of the process and immunogenic antigen output. On the other hand, this invention avoids the sacrifice of animals to stablish primary cell cultures for virus replication, to keep viral reservoires and the usual hazard in virus handling, etc.
SUMMARY OF THE INVENTION
The present invencion puts forth a new process for producing a recombinant subunit vaccine to protect pigs from PPV. The new vaccine produced thus can contain: multiplied in a cell culture of a permissive host (this protein hereinafter optionally refered to as "VP2 hereof") or
The VP2 protein hereof is singularly characterized in forming empty VP2 capsids, optionally incorporating other viral protein epitopes by genetic manipulation of the
REFERENCES:
patent: 4971793 (1990-11-01), Wood et al.
Kajigaya, S. et al. Proc. Natl. Acad. Sci. USA 86:7601-7605 (1989).
Vasudevacharya, J. et al. Virology 173:368-377 (1989).
Molitor, T. W. et al. J. Virology 45(2):842-854 (1983).
Luckow, V. A. et al. Bio/Technology 6:47-55 (1988).
Casal Alvarez Jose I.
Cortes Valdes Elena
Dalsgaard Kristian
Olmo Carmen Vela
Ranz Casares Ana I.
Inmunologia Y Genetica, S.A.
Krsek-Staples Julie
Sidberry Hazel F.
LandOfFree
Recombinant subunit vaccine against porcine parvovirus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant subunit vaccine against porcine parvovirus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant subunit vaccine against porcine parvovirus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2098674